Inhaled corticosteroids, corticosteroid osteoporosis, and the risk of fracture in chronic asthma

Allergy, Asthma and Clinical Immunology

Volumn 1, Issue 1, 2004, Pages 28-33

  Toogood, John H ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; ERGOCALCIFEROL; ESTROGEN; ETIDRONIC ACID; FLUTICASONE; FORMOTEROL; GLUCOCORTICOID; MONTELUKAST; PREDNISONE; RISEDRONIC ACID; SALMETEROL; ZAFIRLUKAST;

ASTHMA; BONE DENSITOMETRY; BONE DENSITY; CHRONIC DISEASE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HUMAN; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; REVIEW; RISK FACTOR;

EID: 33748537343     PISSN: 17101484     EISSN: None     Source Type: Journal    
DOI: 10.2310/7480.2005.00008     Document Type: Review

References (25)

1. Khan AA, Brown JP, Kendler DL, et al. The 2002 Canadian bone densitometry recommendations: take home messsages. Can Med Assoc J 2002;167:1141-5.
2. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. Geneva: World Health Organization; 1994. WHO Technical Report Series No.: 843.
3. Brown JP, Josse RG, for the Scientific Advisory Council of the Osteoporosis Society of Canada. The 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002;167 Suppl):S1-34.
4. Toogood JH, Baskerville JC, Markov AE, et al. Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. J Allergy Clin Immunol 1995;96:157-66.
5. Childhood Asthma Management Program Research Group. Long term effects of budesonide or nedocromil on children with asthma. N Engl J Med 2000;343:1054-63.
6. Lung Health Study Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.
7. Israel E, Bannerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in pre-menopausal women. N Engl J Med 2001;345:941-7.
8. Toogood JH, Hodsman AB, Fraher LJ, et al. Serum osteocalcin and procollagen as markers for the risk of osteoporotic fracture in corticosteroid-treated asthmatic adults. J Allergy Clinlmmunol 1999;104:769-74.
9. Boulet L-P, Becker A, Bérubé D, et al. Canadian asthma consensus report, 1999. Can Med Assoc J 1999;161 Suppl:S1-61.
10. Lau EMC, Woo J, Chan YH, Li M. Alendronate for the prevention of bone loss in patients on inhaled steroid therapy. Bone 2001;29:506-10.
11. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
12. Dawson-Hughes B. Bone loss accompanying medical therapies. N Engl J Med 2001;345:989-91.
13. Dubois EF, Roder E, Deakhuijzen E, et al. Dual energy x-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens. Chest 2002;12:1456-63.
14. Dalsky GP, Stocke KS, Ehsani AA, et al. Weight bearing exercise training and lumbar bone mineral content in post-menopausal women. Ann Intern Med 1998;108:824-8.
15. Holt S, Suder A, Weatherall M, et al. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001; 323:253-6.
16. Nelson HS, Busse WW, deBoisblanc BP, et al. Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. J Allergy Clin Immunol 1999;103:267-75.
17. Nelson HS. Combination treatment with fluticasone/salmeterol in the treatment of asthma. J Allergy Clin Immunol 2001;107:397-416.
18. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-10.
19. Toogood JH, Baskerville JC, Jennings BJ, et al. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J Allergy Clin Immunol 1982;70:288-98.
20. Malo J-L, Cartier A, Merland N, et al. Four times a day dosing frequency is better than a twice-a-day regimen in subjects requiring a high dose inhaled steroid, budesonide, to control moderate to severe asthma. Am Rev Respir Dis 1989;140:625-8.
21. Kozyskj AL, Mustard CA, Cheang MS, et al. Income-based drug-benefit policy: impact on receipt of inhaled corticosteroid prescriptions by Manitoba children with asthma. Can Med Assoc J 2001;165:897-902.
22. Virchow JC Jr, Prasse A, Naya I, et al. Zafirlukast improves asthma control in patients receiving high dose inhaled corticosteroids. Am J Respir Crit Care Med 2000;162:578-85.
23. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis, 2001 update. Arthritis Rheum 2001;44:1496-503.
24. Wong CA, Walsh LJ, Smith CJP, et al. Inhaled corticosteroid use and bone mineral density in patients with asthma. Lancet 2000;355:1399-403.
25. Sambrook PN. Inhaled corticosteroids, bone density, and the risk of fracture. Lancet 2000;355:1385.